Able Innovations is advancing the quality of care, efficiency, and safety in healthcare through user-centric, robotic innovation. Their ALTA Platform® utilizes smart sensors and AI algorithms to facilitate safe and easy patient transfers, allowing a single user to manage transfers at the push of a button. The company is focused on eliminating physical strain on healthcare staff while ensuring patient dignity and comfort during transfers. With a mission driven by empathy and innovation, Able Innovations is positioned to redefine patient handling standards in the healthcare industry.
ACD/Labs develops and commercializes informatics solutions tailored for chemical, biochemical, and pharmaceutical R&D, serving a global client base across various industries. With over 30 years of experience, their software enhances research efficiency, collaboration, and data management, making them a leader in analytical data handling and chemical intelligence. Their products, including the Spectrus and Percepta platforms, are designed to meet the unique needs of R&D teams, ensuring they can innovate faster and make data-driven decisions. ACD/Labs is committed to sustainability and has a strong presence in over 99 countries, with a significant portion of the world's top pharmaceutical companies relying on their solutions.
The best anti-aging resource is your own younger cells. Personalized regenerative medicine is the opportunity to leverage strategies that tap into the power of our own cells to treat our bodies. Our cells have the potential to rejuvenate skin, replenish hair, and even help fight disease. Preserving your own cells today can give you access to your own younger cells to use in revolutionary treatments for the rest of your life.
Allarta Life Science is a pre-clinical regenerative medicine company based in Hamilton, Ontario, Canada, specializing in the development of next-generation biomaterials for immune-privileged delivery of cells, stem cells, and biologics. Their proprietary platform technology aims to overcome immune rejection and prevent cell escape, with a focus on curative cell therapies, particularly for type 1 diabetes. Founded in 2019 by leading researchers in polymer science, Allarta has built a diverse team and an extensive network of collaborators, positioning itself as a key player in the regenerative medicine market.